PT2040548E - Método para o tratamento de distúrbios neurológicos através do aumento da atividade da -glucocerebrosidase - Google Patents

Info

Publication number

PT2040548E

PT2040548E PT07812295T PT07812295T PT2040548E PT 2040548 E PT2040548 E PT 2040548E PT 07812295 T PT07812295 T PT 07812295T PT 07812295 T PT07812295 T PT 07812295T PT 2040548 E PT2040548 E PT 2040548E

Authority

PT

Portugal

Prior art keywords

quot

substituted

isofagomine

unsubstituted

gcase

Prior art date

2006-06-23

Links

• Espacenet
• Global Dossier
• Discuss

• 102000004547 Glucosylceramidase Human genes 0.000 title claims abstract description 105
• 108010017544 Glucosylceramidase Proteins 0.000 title claims abstract description 105
• 230000000694 effects Effects 0.000 title claims abstract description 70
• 238000011282 treatment Methods 0.000 title claims description 37
• 208000012902 Nervous system disease Diseases 0.000 title abstract description 36
• 238000000034 method Methods 0.000 title abstract description 29
• 208000025966 Neurological disease Diseases 0.000 title abstract description 11
• 230000002708 enhancing effect Effects 0.000 title description 5
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 81
• 230000035772 mutation Effects 0.000 claims abstract description 29
• 150000003839 salts Chemical class 0.000 claims description 30
• 208000018737 Parkinson disease Diseases 0.000 claims description 29
• QPYJXFZUIJOGNX-HSUXUTPPSA-N afegostat Chemical compound OC[C@H]1CNC[C@@H](O)[C@@H]1O QPYJXFZUIJOGNX-HSUXUTPPSA-N 0.000 claims description 23
• 208000032859 Synucleinopathies Diseases 0.000 claims description 10
• 239000003814 drug Substances 0.000 claims description 10
• ULBPPCHRAVUQMC-MUMXBIPUSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(3r,4r,5r)-5-(hydroxymethyl)piperidine-3,4-diol Chemical group OC[C@H]1CNC[C@@H](O)[C@@H]1O.OC(=O)[C@H](O)[C@@H](O)C(O)=O ULBPPCHRAVUQMC-MUMXBIPUSA-N 0.000 claims description 8
• 208000009829 Lewy Body Disease Diseases 0.000 claims description 6
• 201000002832 Lewy body dementia Diseases 0.000 claims description 6
• 229940124597 therapeutic agent Drugs 0.000 claims description 6
• 108020002739 Catechol O-methyltransferase Proteins 0.000 claims description 4
• 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 4
• 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 4
• 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims description 3
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 3
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 3
• 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 3
• 239000003954 decarboxylase inhibitor Substances 0.000 claims description 3
• 229960004502 levodopa Drugs 0.000 claims description 3
• 230000001078 anti-cholinergic effect Effects 0.000 claims description 2
• 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
• 102100040999 Catechol O-methyltransferase Human genes 0.000 claims 1
• 208000001089 Multiple system atrophy Diseases 0.000 claims 1
• 239000000556 agonist Substances 0.000 claims 1
• 229960003638 dopamine Drugs 0.000 claims 1
• 108010006519 Molecular Chaperones Proteins 0.000 abstract description 97
• 230000000144 pharmacologic effect Effects 0.000 abstract description 66
• 102000005431 Molecular Chaperones Human genes 0.000 abstract description 35
• 239000003112 inhibitor Substances 0.000 abstract description 32
• 230000001965 increasing effect Effects 0.000 abstract description 26
• 238000001727 in vivo Methods 0.000 abstract description 13
• 210000003169 central nervous system Anatomy 0.000 abstract description 9
• 230000009286 beneficial effect Effects 0.000 abstract description 3
• 102000004190 Enzymes Human genes 0.000 description 107
• 108090000790 Enzymes Proteins 0.000 description 107
• 230000002132 lysosomal effect Effects 0.000 description 74
• 102000004169 proteins and genes Human genes 0.000 description 70
• 235000018102 proteins Nutrition 0.000 description 69
• 210000004027 cell Anatomy 0.000 description 50
• 102000003802 alpha-Synuclein Human genes 0.000 description 43
• 108090000185 alpha-Synuclein Proteins 0.000 description 43
• -1 GlcCer Chemical compound 0.000 description 40
• 150000001875 compounds Chemical class 0.000 description 37
• 210000004556 brain Anatomy 0.000 description 34
• 150000002632 lipids Chemical class 0.000 description 32
• 125000000217 alkyl group Chemical group 0.000 description 27
• 239000000758 substrate Substances 0.000 description 27
• 241000700159 Rattus Species 0.000 description 26
• 230000035508 accumulation Effects 0.000 description 25
• 238000009825 accumulation Methods 0.000 description 25
• 210000003712 lysosome Anatomy 0.000 description 23
• 230000001868 lysosomic effect Effects 0.000 description 23
• 230000002776 aggregation Effects 0.000 description 22
• 238000004220 aggregation Methods 0.000 description 22
• 229910052717 sulfur Inorganic materials 0.000 description 22
• 229910052739 hydrogen Inorganic materials 0.000 description 20
• 125000003118 aryl group Chemical group 0.000 description 19
• 239000001257 hydrogen Substances 0.000 description 19
• 239000000203 mixture Substances 0.000 description 19
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
• LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 17
• 125000000623 heterocyclic group Chemical group 0.000 description 17
• 125000001072 heteroaryl group Chemical group 0.000 description 16
• 210000001320 hippocampus Anatomy 0.000 description 16
• 150000002431 hydrogen Chemical class 0.000 description 16
• 230000004770 neurodegeneration Effects 0.000 description 16
• 239000000243 solution Substances 0.000 description 16
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 15
• 125000000753 cycloalkyl group Chemical group 0.000 description 15
• 229910052760 oxygen Inorganic materials 0.000 description 15
• 229940095064 tartrate Drugs 0.000 description 15
• 241001465754 Metazoa Species 0.000 description 14
• 125000003342 alkenyl group Chemical group 0.000 description 14
• 125000000304 alkynyl group Chemical group 0.000 description 14
• 229910052799 carbon Inorganic materials 0.000 description 14
• 230000002354 daily effect Effects 0.000 description 14
• 208000015122 neurodegenerative disease Diseases 0.000 description 14
• 210000002569 neuron Anatomy 0.000 description 14
• 210000002381 plasma Anatomy 0.000 description 14
• 210000001519 tissue Anatomy 0.000 description 14
• 239000002253 acid Substances 0.000 description 13
• 125000003710 aryl alkyl group Chemical group 0.000 description 13
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 13
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
• 229910052757 nitrogen Inorganic materials 0.000 description 12
• 230000007170 pathology Effects 0.000 description 12
• 238000002360 preparation method Methods 0.000 description 12
• 241000699670 Mus sp. Species 0.000 description 11
• 201000010099 disease Diseases 0.000 description 11
• 238000002560 therapeutic procedure Methods 0.000 description 11
• 125000000392 cycloalkenyl group Chemical group 0.000 description 10
• 238000009472 formulation Methods 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
• 208000015872 Gaucher disease Diseases 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 230000007423 decrease Effects 0.000 description 9
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 9
• 230000001537 neural effect Effects 0.000 description 9
• 230000009467 reduction Effects 0.000 description 9
• 238000006722 reduction reaction Methods 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 238000011830 transgenic mouse model Methods 0.000 description 9
• LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 8
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
• 239000012043 crude product Substances 0.000 description 8
• 230000002255 enzymatic effect Effects 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• 208000024891 symptom Diseases 0.000 description 8
• 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 7
• 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 7
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
• 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 7
• 108090000848 Ubiquitin Proteins 0.000 description 7
• 102000044159 Ubiquitin Human genes 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 230000027455 binding Effects 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 7
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 7
• 150000002305 glucosylceramides Chemical class 0.000 description 7
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
• 230000004060 metabolic process Effects 0.000 description 7
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
• 102000004196 processed proteins & peptides Human genes 0.000 description 7
• 239000000651 prodrug Substances 0.000 description 7
• 229940002612 prodrug Drugs 0.000 description 7
• 239000011541 reaction mixture Substances 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 238000005070 sampling Methods 0.000 description 7
• 239000003981 vehicle Substances 0.000 description 7
• 108010067770 Endopeptidase K Proteins 0.000 description 6
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 241000699660 Mus musculus Species 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• 125000005907 alkyl ester group Chemical group 0.000 description 6
• 125000004432 carbon atom Chemical group C* 0.000 description 6
• 230000015556 catabolic process Effects 0.000 description 6
• 208000031752 chronic bilirubin encephalopathy Diseases 0.000 description 6
• 230000002950 deficient Effects 0.000 description 6
• 208000035475 disorder Diseases 0.000 description 6
• 235000019441 ethanol Nutrition 0.000 description 6
• 238000011156 evaluation Methods 0.000 description 6
• 150000002270 gangliosides Chemical class 0.000 description 6
• 125000005842 heteroatom Chemical group 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• 230000001575 pathological effect Effects 0.000 description 6
• 229920001184 polypeptide Polymers 0.000 description 6
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 5
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
• 229940024606 amino acid Drugs 0.000 description 5
• 235000001014 amino acid Nutrition 0.000 description 5
• 150000001413 amino acids Chemical class 0.000 description 5
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
• 230000002860 competitive effect Effects 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 229910052736 halogen Inorganic materials 0.000 description 5
• 150000002367 halogens Chemical class 0.000 description 5
• 230000002055 immunohistochemical effect Effects 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• 201000006417 multiple sclerosis Diseases 0.000 description 5
• 230000036470 plasma concentration Effects 0.000 description 5
• 239000000741 silica gel Substances 0.000 description 5
• 229910002027 silica gel Inorganic materials 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 230000009261 transgenic effect Effects 0.000 description 5
• 208000033556 type C1 Niemann-Pick disease Diseases 0.000 description 5
• HQRWMZVXYSGFQJ-GMTAPVOTSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-pentylpiperidine-3,4-diol Chemical compound CCCCCN1C[C@@H](O)[C@H](O)[C@@H](CO)C1 HQRWMZVXYSGFQJ-GMTAPVOTSA-N 0.000 description 4
• 101710124976 Beta-hexosaminidase A Proteins 0.000 description 4
• 201000011240 Frontotemporal dementia Diseases 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 4
• 102000004157 Hydrolases Human genes 0.000 description 4
• 108090000604 Hydrolases Proteins 0.000 description 4
• 208000027089 Parkinsonian disease Diseases 0.000 description 4
• 206010034010 Parkinsonism Diseases 0.000 description 4
• 102100036197 Prosaposin Human genes 0.000 description 4
• 101710152403 Prosaposin Proteins 0.000 description 4
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
• 206010044565 Tremor Diseases 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• 150000001721 carbon Chemical group 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 238000006731 degradation reaction Methods 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 230000008030 elimination Effects 0.000 description 4
• 238000003379 elimination reaction Methods 0.000 description 4
• 235000011187 glycerol Nutrition 0.000 description 4
• 150000002339 glycosphingolipids Chemical class 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
• UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 4
• LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical class ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 239000000902 placebo Substances 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 150000003384 small molecules Chemical class 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 210000003523 substantia nigra Anatomy 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• FQBCZWBBRFJEFK-JHJVBQTASA-N (3r,4r,5r)-1-heptyl-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound CCCCCCCN1C[C@@H](O)[C@H](O)[C@@H](CO)C1 FQBCZWBBRFJEFK-JHJVBQTASA-N 0.000 description 3
• ZZQPMCUSRPWYPE-IWSPIJDZSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-(2-methoxyethyl)piperidine-3,4-diol Chemical compound COCCN1C[C@@H](O)[C@H](O)[C@@H](CO)C1 ZZQPMCUSRPWYPE-IWSPIJDZSA-N 0.000 description 3
• PQAUOIYEPRBRRD-GMTAPVOTSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-(3-methylbut-2-enyl)piperidine-3,4-diol Chemical compound CC(C)=CCN1C[C@@H](O)[C@H](O)[C@@H](CO)C1 PQAUOIYEPRBRRD-GMTAPVOTSA-N 0.000 description 3
• VURPXSSEBVGWQX-IWSPIJDZSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-propylpiperidine-3,4-diol Chemical compound CCCN1C[C@@H](O)[C@H](O)[C@@H](CO)C1 VURPXSSEBVGWQX-IWSPIJDZSA-N 0.000 description 3
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 3
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
• 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 3
• XPJWMTPRJTUTBX-CZULRBLNSA-N 2-[(5r,6s,7r,8s)-8-acetamido-6,7-dihydroxy-5-(hydroxymethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl]acetic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)N2C=C(CC(O)=O)N=C12 XPJWMTPRJTUTBX-CZULRBLNSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 206010003694 Atrophy Diseases 0.000 description 3
• 102000006378 Catechol O-methyltransferase Human genes 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
• 208000023105 Huntington disease Diseases 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• XPJWMTPRJTUTBX-UHFFFAOYSA-N Nagstatin Natural products CC(=O)NC1C(O)C(O)C(CO)N2C=C(CC(O)=O)N=C12 XPJWMTPRJTUTBX-UHFFFAOYSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 3
• 239000013504 Triton X-100 Substances 0.000 description 3
• 229920004890 Triton X-100 Polymers 0.000 description 3
• 230000001594 aberrant effect Effects 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 230000032683 aging Effects 0.000 description 3
• 150000001298 alcohols Chemical class 0.000 description 3
• 108010061314 alpha-L-Fucosidase Proteins 0.000 description 3
• 102000012086 alpha-L-Fucosidase Human genes 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 235000010323 ascorbic acid Nutrition 0.000 description 3
• 230000037444 atrophy Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 239000000460 chlorine Substances 0.000 description 3
• 230000006957 competitive inhibition Effects 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 210000005064 dopaminergic neuron Anatomy 0.000 description 3
• 239000003651 drinking water Substances 0.000 description 3
• 235000020188 drinking water Nutrition 0.000 description 3
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 3
• 239000004744 fabric Substances 0.000 description 3
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 238000001415 gene therapy Methods 0.000 description 3
• 238000007429 general method Methods 0.000 description 3
• 125000005843 halogen group Chemical group 0.000 description 3
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
• 125000001183 hydrocarbyl group Chemical group 0.000 description 3
• FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 125000005647 linker group Chemical group 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
• 230000036963 noncompetitive effect Effects 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 230000003285 pharmacodynamic effect Effects 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000004845 protein aggregation Effects 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 231100000279 safety data Toxicity 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 230000006641 stabilisation Effects 0.000 description 3
• 238000011105 stabilization Methods 0.000 description 3
• 125000001424 substituent group Chemical group 0.000 description 3
• 108060007951 sulfatase Proteins 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 230000004797 therapeutic response Effects 0.000 description 3
• 229940099072 zavesca Drugs 0.000 description 3
• GGYKFWIOFOPIFH-MGPQQGTHSA-N (3r,4r,5r)-1-(2-cyclohexylethyl)-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CCC1CCCCC1 GGYKFWIOFOPIFH-MGPQQGTHSA-N 0.000 description 2
• YGNUTUJHYUAUCX-JHJVBQTASA-N (3r,4r,5r)-1-(cyclohexylmethyl)-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CC1CCCCC1 YGNUTUJHYUAUCX-JHJVBQTASA-N 0.000 description 2
• GTLQXRMLXLQXBJ-IJLUTSLNSA-N (3r,4r,5r)-1-(cyclopentylmethyl)-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CC1CCCC1 GTLQXRMLXLQXBJ-IJLUTSLNSA-N 0.000 description 2
• AYTXWKIAYUJDTC-FBIMIBRVSA-N (3r,4r,5r)-1-(furan-2-ylmethyl)-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CC1=CC=CO1 AYTXWKIAYUJDTC-FBIMIBRVSA-N 0.000 description 2
• LVUCVLGHEJMJMX-RAIGVLPGSA-N (3r,4r,5r)-1-[(4-aminophenyl)methyl]-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound C1=CC(N)=CC=C1CN1C[C@H](CO)[C@@H](O)[C@H](O)C1 LVUCVLGHEJMJMX-RAIGVLPGSA-N 0.000 description 2
• IJAGUXHRYPNJAM-RAIGVLPGSA-N (3r,4r,5r)-1-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CC1=CC=C(F)C=C1 IJAGUXHRYPNJAM-RAIGVLPGSA-N 0.000 description 2
• SGPVIQCAOCSXHN-JHJVBQTASA-N (3r,4r,5r)-1-benzyl-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CC1=CC=CC=C1 SGPVIQCAOCSXHN-JHJVBQTASA-N 0.000 description 2
• VWVVWPRLKKRBBX-YUSALJHKSA-N (3r,4r,5r)-1-cyclohexyl-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1C1CCCCC1 VWVVWPRLKKRBBX-YUSALJHKSA-N 0.000 description 2
• YHOKUSQHIOHUDJ-MGPQQGTHSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-(2-phenylethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CCC1=CC=CC=C1 YHOKUSQHIOHUDJ-MGPQQGTHSA-N 0.000 description 2
• BMZCRDKQUUDUMG-IJLUTSLNSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-(4-methylpentyl)piperidine-3,4-diol Chemical compound CC(C)CCCN1C[C@@H](O)[C@H](O)[C@@H](CO)C1 BMZCRDKQUUDUMG-IJLUTSLNSA-N 0.000 description 2
• CQVRHCPRHKKMJS-IJLUTSLNSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-(oxan-4-ylmethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CC1CCOCC1 CQVRHCPRHKKMJS-IJLUTSLNSA-N 0.000 description 2
• RYBXNLJWPSALOR-IJLUTSLNSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-(piperidin-4-ylmethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CC1CCNCC1 RYBXNLJWPSALOR-IJLUTSLNSA-N 0.000 description 2
• HEUKMGNKIWGRQK-IJLUTSLNSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-(pyridin-4-ylmethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CC1=CC=NC=C1 HEUKMGNKIWGRQK-IJLUTSLNSA-N 0.000 description 2
• KCZNVTQEXHDTJB-FBIMIBRVSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-(thiophen-2-ylmethyl)piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CC1=CC=CS1 KCZNVTQEXHDTJB-FBIMIBRVSA-N 0.000 description 2
• FBYMXLLBYHENBK-MGPQQGTHSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-[(2-methylphenyl)methyl]piperidine-3,4-diol Chemical compound CC1=CC=CC=C1CN1C[C@H](CO)[C@@H](O)[C@H](O)C1 FBYMXLLBYHENBK-MGPQQGTHSA-N 0.000 description 2
• KKYOXNWQRVZXFR-MGPQQGTHSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-[(3-methylphenyl)methyl]piperidine-3,4-diol Chemical compound CC1=CC=CC(CN2C[C@H](CO)[C@@H](O)[C@H](O)C2)=C1 KKYOXNWQRVZXFR-MGPQQGTHSA-N 0.000 description 2
• XBUOSFJCSXGHNU-MRVWCRGKSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-[(4-methoxyphenyl)methyl]piperidine-3,4-diol Chemical compound C1=CC(OC)=CC=C1CN1C[C@H](CO)[C@@H](O)[C@H](O)C1 XBUOSFJCSXGHNU-MRVWCRGKSA-N 0.000 description 2
• RYIRWESPUZPXRZ-MGPQQGTHSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-[(4-methylphenyl)methyl]piperidine-3,4-diol Chemical compound C1=CC(C)=CC=C1CN1C[C@H](CO)[C@@H](O)[C@H](O)C1 RYIRWESPUZPXRZ-MGPQQGTHSA-N 0.000 description 2
• DGFRDGKPVOHULX-GUDVDZBRSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-[(4-phenylphenyl)methyl]piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CC1=CC=C(C=2C=CC=CC=2)C=C1 DGFRDGKPVOHULX-GUDVDZBRSA-N 0.000 description 2
• QPYJXFZUIJOGNX-PBXRRBTRSA-N (3r,4s,5r)-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound OC[C@H]1CNC[C@@H](O)[C@H]1O QPYJXFZUIJOGNX-PBXRRBTRSA-N 0.000 description 2
• RZRDQZQPTISYKY-MVIOUDGNSA-N (5r,6r,7s,8s)-5-(hydroxymethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6,7,8-triol Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C2=NC=CN12 RZRDQZQPTISYKY-MVIOUDGNSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 description 2
• QPYJXFZUIJOGNX-UHFFFAOYSA-N 5-(hydroxymethyl)piperidine-3,4-diol Chemical compound OCC1CNCC(O)C1O QPYJXFZUIJOGNX-UHFFFAOYSA-N 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 102100026882 Alpha-synuclein Human genes 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
• 208000000044 Amnesia Diseases 0.000 description 2
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 206010003591 Ataxia Diseases 0.000 description 2
• 101710124978 Beta-hexosaminidase B Proteins 0.000 description 2
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
• 206010006100 Bradykinesia Diseases 0.000 description 2
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
• 229920001268 Cholestyramine Polymers 0.000 description 2
• ZHMWOVGZCINIHW-SPHYCDKFSA-N Conduritol-beta-epoxide Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C2OC21 ZHMWOVGZCINIHW-SPHYCDKFSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 201000008905 GM2 gangliosidosis Diseases 0.000 description 2
• 208000009796 Gangliosidoses Diseases 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108010060309 Glucuronidase Proteins 0.000 description 2
• 102000053187 Glucuronidase Human genes 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 229930186217 Glycolipid Natural products 0.000 description 2
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
• 208000004547 Hallucinations Diseases 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
• 208000006083 Hypokinesia Diseases 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Chemical class CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 108010006232 Neuraminidase Proteins 0.000 description 2
• 102000005348 Neuraminidase Human genes 0.000 description 2
• 206010060860 Neurological symptom Diseases 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 108010068086 Polyubiquitin Proteins 0.000 description 2
• 102100037935 Polyubiquitin-C Human genes 0.000 description 2
• AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 102000005262 Sulfatase Human genes 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 102000019355 Synuclein Human genes 0.000 description 2
• 108050006783 Synuclein Proteins 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 125000004946 alkenylalkyl group Chemical group 0.000 description 2
• 125000004450 alkenylene group Chemical group 0.000 description 2
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 150000003973 alkyl amines Chemical class 0.000 description 2
• 108010012864 alpha-Mannosidase Proteins 0.000 description 2
• 102000019199 alpha-Mannosidase Human genes 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 125000000129 anionic group Chemical group 0.000 description 2
• 230000003466 anti-cipated effect Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
• 230000007455 autophagic response Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 102000006995 beta-Glucosidase Human genes 0.000 description 2
• 108010047754 beta-Glucosidase Proteins 0.000 description 2
• 150000001642 boronic acid derivatives Chemical class 0.000 description 2
• 210000000133 brain stem Anatomy 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 210000004720 cerebrum Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 230000001876 chaperonelike Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 239000007979 citrate buffer Substances 0.000 description 2
• 150000001860 citric acid derivatives Chemical class 0.000 description 2
• 238000012790 confirmation Methods 0.000 description 2
• 230000001054 cortical effect Effects 0.000 description 2
• 125000004093 cyano group Chemical group *C#N 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000000593 degrading effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Chemical class CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
• 230000003292 diminished effect Effects 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 238000001952 enzyme assay Methods 0.000 description 2
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 229960000815 ezetimibe Drugs 0.000 description 2
• 229960002297 fenofibrate Drugs 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 201000006440 gangliosidosis Diseases 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 125000001188 haloalkyl group Chemical group 0.000 description 2
• LIIALPBMIOVAHH-UHFFFAOYSA-N herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 2
• JHGVLAHJJNKSAW-UHFFFAOYSA-N herniarin Natural products C1CC(=O)OC2=CC(OC)=CC=C21 JHGVLAHJJNKSAW-UHFFFAOYSA-N 0.000 description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 230000003301 hydrolyzing effect Effects 0.000 description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• 210000003000 inclusion body Anatomy 0.000 description 2
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 239000013038 irreversible inhibitor Substances 0.000 description 2
• QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 210000004558 lewy body Anatomy 0.000 description 2
• 230000037356 lipid metabolism Effects 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• ZLQJVGSVJRBUNL-UHFFFAOYSA-N methylumbelliferone Natural products C1=C(O)C=C2OC(=O)C(C)=CC2=C1 ZLQJVGSVJRBUNL-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 230000016273 neuron death Effects 0.000 description 2
• 235000001968 nicotinic acid Nutrition 0.000 description 2
• 229960003512 nicotinic acid Drugs 0.000 description 2
• 239000011664 nicotinic acid Substances 0.000 description 2
• 125000004433 nitrogen atom Chemical group N* 0.000 description 2
• 231100001079 no serious adverse effect Toxicity 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000007331 pathological accumulation Effects 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 238000011422 pharmacological therapy Methods 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000011574 phosphorus Chemical group 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 230000001144 postural effect Effects 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• 230000004952 protein activity Effects 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 239000003642 reactive oxygen metabolite Substances 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 150000003873 salicylate salts Chemical class 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000004334 sorbic acid Substances 0.000 description 2
• 235000010199 sorbic acid Nutrition 0.000 description 2
• 229940075582 sorbic acid Drugs 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 235000010356 sorbitol Nutrition 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 230000035882 stress Effects 0.000 description 2
• 125000003107 substituted aryl group Chemical group 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 239000011593 sulfur Chemical group 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 210000000225 synapse Anatomy 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• PFYHYHZGDNWFIF-UHFFFAOYSA-N (+)-DMDP Natural products OCC1NC(CO)C(O)C1O PFYHYHZGDNWFIF-UHFFFAOYSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
• HHJTWTPUPVQKNA-SKXACSAKSA-N (2r,3s,4s,5s,6r)-2-[(e,3r)-2-amino-3-hydroxyoctadec-4-enoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)C(N)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HHJTWTPUPVQKNA-SKXACSAKSA-N 0.000 description 1
• YRBKDBZXOAEMOT-VANKVMQKSA-N (2s,3s,4s,5r)-2-(hydroxymethyl)-5-methylpyrrolidine-3,4-diol Chemical compound C[C@H]1N[C@@H](CO)[C@H](O)[C@H]1O YRBKDBZXOAEMOT-VANKVMQKSA-N 0.000 description 1
• PUVBDYZJWIEJKE-RAIGVLPGSA-N (3r,4r,5r)-5-(hydroxymethyl)-1-[(4-nitrophenyl)methyl]piperidine-3,4-diol Chemical compound C1[C@@H](O)[C@H](O)[C@@H](CO)CN1CC1=CC=C([N+]([O-])=O)C=C1 PUVBDYZJWIEJKE-RAIGVLPGSA-N 0.000 description 1
• ANLDCFKLHJOZGD-OPGJLUCNSA-N (5r,6r,7s,8s)-2-(3,3-dimethylbut-1-ynyl)-6,7,8-tris(phenylmethoxy)-5-(phenylmethoxymethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine Chemical compound C([C@H]1N2C=C(N=C2[C@H](OCC=2C=CC=CC=2)[C@@H](OCC=2C=CC=CC=2)[C@@H]1OCC=1C=CC=CC=1)C#CC(C)(C)C)OCC1=CC=CC=C1 ANLDCFKLHJOZGD-OPGJLUCNSA-N 0.000 description 1
• CFJPBGQYMKXSJT-WISYIIOYSA-N (5r,6r,7s,8s)-2-(3,3-dimethylbutyl)-5-(hydroxymethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6,7,8-triol Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C2=NC(CCC(C)(C)C)=CN21 CFJPBGQYMKXSJT-WISYIIOYSA-N 0.000 description 1
• LPCXHNKOVDPQOD-KIPVPBBYSA-N (5r,6r,7s,8s)-2-iodo-6,7,8-tris(phenylmethoxy)-5-(phenylmethoxymethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine Chemical compound C([C@H]1N2C=C(N=C2[C@H](OCC=2C=CC=CC=2)[C@@H](OCC=2C=CC=CC=2)[C@@H]1OCC=1C=CC=CC=1)I)OCC1=CC=CC=C1 LPCXHNKOVDPQOD-KIPVPBBYSA-N 0.000 description 1
• OMVDIWMZQBJVFN-APIJFGDWSA-N (5r,6r,7s,8s)-5-(hydroxymethyl)-2-octyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6,7,8-triol Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C2=NC(CCCCCCCC)=CN21 OMVDIWMZQBJVFN-APIJFGDWSA-N 0.000 description 1
• 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• PFYHYHZGDNWFIF-KVTDHHQDSA-N 2,5-bis(hydroxymethyl)-3,4-dihydroxypyrrolidine Chemical compound OC[C@H]1N[C@H](CO)[C@@H](O)[C@@H]1O PFYHYHZGDNWFIF-KVTDHHQDSA-N 0.000 description 1
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
• IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
• IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
• PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
• MWGATWIBSKHFMR-UHFFFAOYSA-N 2-anilinoethanol Chemical compound OCCNC1=CC=CC=C1 MWGATWIBSKHFMR-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• KIZQNNOULOCVDM-UHFFFAOYSA-M 2-hydroxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].C[N+](C)(C)CCO KIZQNNOULOCVDM-UHFFFAOYSA-M 0.000 description 1
• 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
• 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
• KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical class OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
• 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
• 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
• PFYHYHZGDNWFIF-OMMKOOBNSA-N 2R,5R-Dihydroxymethyl-3R,4R-dihydroxy-pyrrolidine Natural products OC[C@@H]1N[C@@H](CO)[C@H](O)[C@@H]1O PFYHYHZGDNWFIF-OMMKOOBNSA-N 0.000 description 1
• 125000005986 4-piperidonyl group Chemical group 0.000 description 1
• HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
• YRBKDBZXOAEMOT-UHFFFAOYSA-N 6-deoxy-DMDP Natural products CC1NC(CO)C(O)C1O YRBKDBZXOAEMOT-UHFFFAOYSA-N 0.000 description 1
• DQTKLICLJUKNCG-UHFFFAOYSA-N A-72363 A-1 Natural products CC(=O)NC1NCC(C(O)=O)C(O)C1O DQTKLICLJUKNCG-UHFFFAOYSA-N 0.000 description 1
• 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
• 108091006112 ATPases Proteins 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102000006772 Acid Ceramidase Human genes 0.000 description 1
• 108020005296 Acid Ceramidase Proteins 0.000 description 1
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
• 208000006888 Agnosia Diseases 0.000 description 1
• 241001047040 Agnosia Species 0.000 description 1
• 208000011403 Alexander disease Diseases 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 208000031091 Amnestic disease Diseases 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010003062 Apraxia Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 102100031491 Arylsulfatase B Human genes 0.000 description 1
• 102000009133 Arylsulfatases Human genes 0.000 description 1
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
• 238000012935 Averaging Methods 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
• 102100032487 Beta-mannosidase Human genes 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
• 208000022526 Canavan disease Diseases 0.000 description 1
• 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
• JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
• 102000005600 Cathepsins Human genes 0.000 description 1
• 108010084457 Cathepsins Proteins 0.000 description 1
• 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 206010008754 Choreoathetosis Diseases 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 241001573498 Compacta Species 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 206010011985 Decubitus ulcer Diseases 0.000 description 1
• 206010012239 Delusion Diseases 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
• 208000014094 Dystonic disease Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 230000006782 ER associated degradation Effects 0.000 description 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
• 206010015548 Euthanasia Diseases 0.000 description 1
• 206010015958 Eye pain Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 208000001905 GM2 Gangliosidoses Diseases 0.000 description 1
• 208000020322 Gaucher disease type I Diseases 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• QMXOFBXZEKTJIK-UHFFFAOYSA-N Glycinol Natural products C1=C(O)C=C2OCC3(O)C4=CC=C(O)C=C4OC3C2=C1 QMXOFBXZEKTJIK-UHFFFAOYSA-N 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 206010019075 Hallucination, visual Diseases 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 description 1
• 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 1
• 101710096421 Iduronate 2-sulfatase Proteins 0.000 description 1
• 108010003381 Iduronidase Proteins 0.000 description 1
• 102000004627 Iduronidase Human genes 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 208000015439 Lysosomal storage disease Diseases 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108010054377 Mannosidases Proteins 0.000 description 1
• 102000001696 Mannosidases Human genes 0.000 description 1
• 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 1
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
• XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 102000010909 Monoamine Oxidase Human genes 0.000 description 1
• 108010062431 Monoamine oxidase Proteins 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 1
• FOCMISOLVPZNSV-CANPYCKCSA-N N-[(E,2R,3S)-1-[5-[5-[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3NC(C)=O)C(O)C2O)C(O)C1O)[C@@H](O)\C=C\CCCCCCCCCCCCC FOCMISOLVPZNSV-CANPYCKCSA-N 0.000 description 1
• 108010023320 N-acetylglucosamine-6-sulfatase Proteins 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 208000014060 Niemann-Pick disease Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 239000008118 PEG 6000 Substances 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 206010034719 Personality change Diseases 0.000 description 1
• 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
• 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
• 208000004210 Pressure Ulcer Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 229940079156 Proteasome inhibitor Drugs 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 208000006289 Rett Syndrome Diseases 0.000 description 1
• 101150110423 SNCA gene Proteins 0.000 description 1
• 208000021811 Sandhoff disease Diseases 0.000 description 1
• 102000017852 Saposin Human genes 0.000 description 1
• 108050007079 Saposin Proteins 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
• 208000000323 Tourette Syndrome Diseases 0.000 description 1
• 208000016620 Tourette disease Diseases 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 229920004929 Triton X-114 Polymers 0.000 description 1
• 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
• 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 125000004442 acylamino group Chemical group 0.000 description 1
• 125000004423 acyloxy group Chemical group 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 150000005215 alkyl ethers Chemical class 0.000 description 1
• 230000008850 allosteric inhibition Effects 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• 108010028144 alpha-Glucosidases Proteins 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 108010061261 alpha-glucuronidase Proteins 0.000 description 1
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 238000005576 amination reaction Methods 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 230000006986 amnesia Effects 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 239000003529 anticholesteremic agent Substances 0.000 description 1
• 229940127226 anticholesterol agent Drugs 0.000 description 1
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 210000002376 aorta thoracic Anatomy 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 150000007860 aryl ester derivatives Chemical class 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
• 230000003416 augmentation Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000002886 autophagic effect Effects 0.000 description 1
• 125000002785 azepinyl group Chemical group 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 210000004227 basal ganglia Anatomy 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
• HHJTWTPUPVQKNA-JIAPQYILSA-N beta-D-glucosylsphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HHJTWTPUPVQKNA-JIAPQYILSA-N 0.000 description 1
• 108010055059 beta-Mannosidase Proteins 0.000 description 1
• 108090000182 beta-Synuclein Proteins 0.000 description 1
• 102000003799 beta-Synuclein Human genes 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 239000000337 buffer salt Substances 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• XOCBOVUINUHZJA-UHFFFAOYSA-N calystegine A3 Natural products OC1C(O)CC2CCC1(O)N2 XOCBOVUINUHZJA-UHFFFAOYSA-N 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 235000013877 carbamide Nutrition 0.000 description 1
• 125000005242 carbamoyl alkyl group Chemical group 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 210000005242 cardiac chamber Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000006652 catabolic pathway Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 206010008129 cerebral palsy Diseases 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 239000000812 cholinergic antagonist Substances 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 231100000868 delusion Toxicity 0.000 description 1
• 230000005016 dendritic process Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 229960003914 desipramine Drugs 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 229960001985 dextromethorphan Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
• 125000005879 dioxolanyl group Chemical group 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 238000003182 dose-response assay Methods 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 208000010118 dystonia Diseases 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000001163 endosome Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000009088 enzymatic function Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 229940125753 fibrate Drugs 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000002073 fluorescence micrograph Methods 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 210000005153 frontal cortex Anatomy 0.000 description 1
• 230000007849 functional defect Effects 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 150000002256 galaktoses Chemical class 0.000 description 1
• GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 1
• 238000004817 gas chromatography Methods 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 229940045109 genistein Drugs 0.000 description 1
• TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
• 235000006539 genistein Nutrition 0.000 description 1
• ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
• 230000007387 gliosis Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 150000002315 glycerophosphates Chemical class 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 150000002357 guanidines Chemical class 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 108010089932 heparan sulfate sulfatase Proteins 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 208000006663 kernicterus Diseases 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 208000036546 leukodystrophy Diseases 0.000 description 1
• 230000006372 lipid accumulation Effects 0.000 description 1
• 229940002661 lipitor Drugs 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 108010045758 lysosomal proteins Proteins 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 210000001259 mesencephalon Anatomy 0.000 description 1
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
• 229960003105 metformin Drugs 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 230000002025 microglial effect Effects 0.000 description 1
• 230000007388 microgliosis Effects 0.000 description 1
• 229960001512 miglustat Drugs 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
• 235000019799 monosodium phosphate Nutrition 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• WNYIBZHOMJZDKN-UHFFFAOYSA-N n-(2-acetamidoethyl)acetamide Chemical compound CC(=O)NCCNC(C)=O WNYIBZHOMJZDKN-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 210000000478 neocortex Anatomy 0.000 description 1
• 210000001577 neostriatum Anatomy 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000007658 neurological function Effects 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 230000006776 neuronal homeostasis Effects 0.000 description 1
• 230000008906 neuronal response Effects 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 230000006959 non-competitive inhibition Effects 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
• 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
• 201000005111 ocular hyperemia Diseases 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 125000004043 oxo group Chemical group O=* 0.000 description 1
• 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 102000045222 parkin Human genes 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 238000011458 pharmacological treatment Methods 0.000 description 1
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 239000007981 phosphate-citrate buffer Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229940068977 polysorbate 20 Drugs 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 230000026938 proteasomal ubiquitin-dependent protein catabolic process Effects 0.000 description 1
• 239000003207 proteasome inhibitor Substances 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 230000022558 protein metabolic process Effects 0.000 description 1
• 230000004063 proteosomal degradation Effects 0.000 description 1
• 230000007111 proteostasis Effects 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 210000002637 putamen Anatomy 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 229940073095 questran Drugs 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 238000006268 reductive amination reaction Methods 0.000 description 1
• 238000005057 refrigeration Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000003716 rejuvenation Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 230000009758 senescence Effects 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• DQTKLICLJUKNCG-ZTYPAOSTSA-N siastatin b Chemical compound CC(=O)N[C@H]1NC[C@H](C(O)=O)[C@H](O)[C@@H]1O DQTKLICLJUKNCG-ZTYPAOSTSA-N 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• CIJQGPVMMRXSQW-UHFFFAOYSA-M sodium;2-aminoacetic acid;hydroxide Chemical compound O.[Na+].NCC([O-])=O CIJQGPVMMRXSQW-UHFFFAOYSA-M 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000007847 structural defect Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 125000004426 substituted alkynyl group Chemical group 0.000 description 1
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
• 210000004281 subthalamic nucleus Anatomy 0.000 description 1
• 150000003890 succinate salts Chemical class 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
• FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
• 229960005566 swainsonine Drugs 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• KHVCOYGKHDJPBZ-WDCZJNDASA-N tetrahydrooxazine Chemical compound OC[C@H]1ONC[C@@H](O)[C@@H]1O KHVCOYGKHDJPBZ-WDCZJNDASA-N 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 235000019157 thiamine Nutrition 0.000 description 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• 239000011721 thiamine Substances 0.000 description 1
• 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
• 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 125000005270 trialkylamine group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000002562 urinalysis Methods 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 229940051223 zetia Drugs 0.000 description 1